Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06466382
Other study ID # Swiss-GO-08/ OV Precision
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date September 2024
Est. completion date December 2027

Study information

Verified date March 2024
Source Swiss GO Trial Group
Contact Maren S Vogel, PhD
Phone +41 61 3284203
Email maren.vogel@usb.ch
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The long-term goal of this research project is to demonstrate whether HRD negative (HPR) patients benefit when additional multimodal biological tumor information is incorporated into the molecular tumor board (mTB) treatment recommendation process.


Description:

Homologous recombination proficient (HRP) or HRD negative (HRDneg) Ovarain Cancer (OC) patients have a poor outcome equivalent to platinum-resistant patients (PFS 11.5 months;.Given standard of care chemotherapy is not ideal for 50% of EOC and this patient population urgently needs alternative treatment options tailored to their individual tumor profile. Treatment options for the heterogeneous HRDneg patient group are scarceand mainly focus on symptom control and palliation, delaying time to symptomatic progression, and improving QoL. Therefore, trials at initial diagnosis, when the patient can still be cured and is treatment naïve, are urgently needed. The intervention studied is a personalized treatment recommendation by a specialized molecular tumorboard. This recommendation is based on a Molecular summary report (MSR) which is created by multi-modal Tumor Profiling (TP) , i.e., molecular analysis of clinical specimens, obtained from the individual participant. TP, a technology platform of several precision-cancer profiling domains established by the TPC (= Tumor Profiler Center, Switzerland), It combines and rates the most efficient drugs/ experimental treatments for an individual ovarian cancer patient independent of standard of care (SOC). The usability in clinical practice of this recommendation will be tested. It should support the clinical decision of the treating oncologists and patients to choose the best possible therapy for the individual patient. Treatment recommendations on the most appropriate molecular-based treatment for the individual patient are formulated based on the expertise and experience of the mTB board members. Additionally, a MSR from validated TP technology platform can serve as further guidance in the tumorboard. However, the final decision on initial treatment remains at the discretion of the treating physician and the patient. OV Precision is a multicenter randomized (1:1) controlled trial comparing a personalized treatment recommendation at the discretion of the treating physician in agreement with the patient versus SOC without receiving a mTB recommendation. The study will be divided into two phases: an initial diagnostic phase, in which presumed eligible patients will be recruited into the study, HRD status will be determined, and tumor profiling will be performed in HRDneg patients with a confirmed diagnosis. Eligible patients will be randomized and treated according to their group allocation in the second phase (treatment phase). The study duration is planned for 3 years including analysis: Two years of recruitment (starting from 09/2024), final analysis of the focal endpoints and end of the study 10 weeks after inclusion of the last patient (12/2026). Study analysis and publication should be completed approximately one year later (12/2027).


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 60
Est. completion date December 2027
Est. primary completion date September 2026
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - Newly diagnosed EOC and carcinosarcoma patients with a suspected FIGO Stage III and IV - No immediate need of systemic or surgical treatment at time of and until 2 weeks after diagnosis - Envisaged surgical candidate for interval debulking after 2 cycles of treatment - Willing and able to attend the visits, to understand the purpose of the trial and all trial-related procedures - ECOG 0-2 - Written informed consent according to national legal and regulatory requirements prior to any project specific procedures Exclusion Criteria: - Elevated liver enzymes (double of normal range) - Elevated creatinine (double of normal range ) - ECOG =3 - Pregnant or lactating women - Any other malignancy within the last 5 years which has an impact on the prognosis of the patient - Inability to swallow tablets - Concurrent participation in another clinical trial on the same indication - Any other serious underlying medical, psychiatric, psychological, familial, or geographical condition, which in the judgment of the sponsor-project leader may interfere with the project or affect patient compliance

Study Design


Intervention

Other:
Treatment recommenation by molecular tumnor board based on tumpor profiling
The intervention studied is a treatment recommendation by a specialized molecular tumorboard. This recommendation is based on a MSR which is created by TP, i.e., molecular analysis of clinical specimens, obtained from the individual participant. TP, a technology platform of several precision-cancer profiling domains, combines and rates the most efficient drugs/ experimental treatments for an individual ovarian cancer patient independent of standard of care. The usability in clinical practice of this recommendation will be tested. It should support the clinical decision of the treating oncologists and patients to choose the best possible therapy for the individual patient.
Drug:
Carboplatin / Paclitaxel Chemotherapy
2 cycles of chemotherapy with carboplatin AUC5 3-weekly and paclitaxel 175 mg/m2 3-weekly or carboplatin AUC2 weekly and Paclitaxel 60-80mg/m2 weekly

Locations

Country Name City State
Switzerland Universitätsspital Basel Basel Basel Stadt

Sponsors (2)

Lead Sponsor Collaborator
Swiss GO Trial Group Tumor Profiler Center Switzerland

Country where clinical trial is conducted

Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Focal Outcome Measure (FOM) 1 of pilot study: Proportion of patients for whom the molecular Tumor Board (mTB) considers a different treatment option Number (proportion) of cases in which the Tumor Profiling (TP) was able to generate a conclusive Molecular Summary Report (MSR)
Number (proportion) of cases in which the mTB considers the MSR as useful support for making a treatment recommendation on a scale from zero (not useful at all) to five (very useful)
2-3 weeks
Primary FOM 2 of pilot study: Investigation whether the treating oncologist feels better supported by the mTB recommendation considers the additional biological tumor information than by the standard of care where such information is not considered. Number (proportion) of cases in which the treating physician considers the mTB recommendation as useful for making a final treatment decision on a scale from zero (not useful at all) to five (very useful).
Definition of molecular results from TP that cannot be used for clinical decision making.
Definition of an algorithm for the decision process from MSR to treatment recommendation.
2-3 weeks
Primary FOM 3 of pilot study: Investigation of different treatment decisions by the patient and the treating oncologist. Number of therapy adaptations in the exploratory arm based on the MSR.
Number (proportion) of cases with therapy adaptions with minor / major/ no change from SOC.
Number (proportion) of treatment recommendations by mTB which were followed by the doctor and patient in the window of opportunity.
Number (proportion) of treatment recommendations by mTB which were continued by the doctor and patient after the trial and after finishing SOC.
Number (proportion) of treatment recommendations by mTB which were not followed by the doctor and patient in the window of opportunity due to restrictions.
Differences in hypothetical treatment costs between SOC and exploratory arm.
4 weeks
Primary FOM 4 of pilot study: Preliminary estimate of the actual patient benefit of the intervention in terms of a number of patient-relevant outcomes. The difference in proportions of responders between the standard of care and experimental arm after interval debulking surgery or biopsy at second specimen collection time point (week 10). A patient is classified as a responder if at least one of the two conditions is met: The Chemotherapy Response Score (CRS) is larger than or equal to 2 or the CA125 KELIM score is larger than or equal to 1.
Note A : The three-tired CRS ranges from 1 (no or minimal tumor response) to 3 (total or near-total tumor response) .
Note B: The tumormarker CA125 level decline (= CA125 KELIM ) over at least 3 timepoints can give an indication of therapy response. A favourable KELIM score = 1.0,Unfavorable KELIM score < 1.
Symptoms measured by MOST- S26 questionnaire from V1 (baseline at diagnosis) until V9 (EOT), in both arms.
Qualitiy of Life (QoL): Questionnaires EORTC QLQ-C30, EORTC QLQ-OV28 from V1 (baseline at diagnosis) until V9 (EOT), in both arms.
10 weeks
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03648489 - Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma) Phase 2
Completed NCT00415181 - Pharmacogenomics of Paclitaxel in Ovarian Cancer N/A
Completed NCT00063401 - Phase II Study in Patients With Epidermal Growth Factor Receptor (EGFR) + Advanced Stage Ovarian, Primary Peritoneal and Fallopian Tube Cancer Phase 2
Completed NCT00035100 - EPO906 Therapy in Patients With Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer Phase 2
Withdrawn NCT01228942 - A Prospective Trial of COXEN Chemotherapy Prediction N/A
Completed NCT00074867 - Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 To Treat Small-Volume Ovarian, Peritoneal, Fallopian Tube Cancer Phase 2
Completed NCT00191646 - An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemotherapy Phase 3
Recruiting NCT05960630 - MIRRORS-RCT Pilot: Role of Robotic Interval Cytoreductive Surgery for Advanced Ovarian Cancer N/A
Completed NCT01846611 - A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Phase 3
Recruiting NCT04556071 - Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer Phase 2
Recruiting NCT04111978 - MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO) Phase 3
Withdrawn NCT01766622 - 18F-CP18 Imaging Studies for Cancer Treatment With Birinapant Phase 2
Recruiting NCT05617755 - AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer Phase 1
Completed NCT01478685 - A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors Phase 1
Completed NCT02903771 - Phase I Study of Cantrixil in Patients With Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer. Phase 1
Completed NCT01462890 - Evaluation of Optimal Treatment Duration of Bevacizumab Combination With Standard Chemotherapy in Patients With Ovarian Cancer Phase 3
Completed NCT00391118 - Comparing Two Treatments for Ovarian Cancer: Standard Chemotherapy Plus Enzastaurin, or Placebo ("Sugar Pill") Phase 2
Terminated NCT00407407 - ABI-007 With Carboplatin as First-Line Therapy in Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma Phase 1
Completed NCT00189345 - Randomized, Multicenter, 2-Dose Level. Open-Label, Phase IIa Study With the Intraperitoneally Infused Trifunctional Bispecific Antibody Removab(TM) (Anti-EpCAM x Anti-CD3) to Select the Better Dose Level in Platinum Refractory Epithelial Ovarian Cancer Patients Phase 2
Completed NCT00443196 - Testing Drug Sensitivity of Ovarian, Fallopian and Primary Peritoneal Adenocarcinomas Phase 2/Phase 3